Gender differences in the response to antipsychotic medication in patients with schizophrenia: An individual patient data meta-analysis of placebo-controlled studies.

Autor: Storosum BWC; Department of Psychiatry, Amsterdam UMC, Amsterdam Neuroscience, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: b.w.storosum@amsterdamumc.nl., Mattila T; Medicines Evaluation Board, Utrecht, The Netherlands., Wohlfarth TD; Medicines Evaluation Board, Utrecht, The Netherlands., Gispen-de Wied CC; Medicines Evaluation Board, Utrecht, The Netherlands., Roes KCB; Medicines Evaluation Board, Utrecht, The Netherlands; Department for Health Evidence Biostatistics Research Group Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., den Brink WV; Department of Psychiatry, Amsterdam UMC, Amsterdam Neuroscience, University of Amsterdam, Amsterdam, The Netherlands., de Haan L; Department of Psychiatry, Amsterdam UMC, Amsterdam Neuroscience, University of Amsterdam, Amsterdam, The Netherlands; Arkin Institute for Mental Health, Amsterdam, The Netherlands., Denys DAJP; Department of Psychiatry, Amsterdam UMC, Amsterdam Neuroscience, University of Amsterdam, Amsterdam, The Netherlands; Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands., Zantvoord JB; Department of Psychiatry, Amsterdam UMC, Amsterdam Neuroscience, University of Amsterdam, Amsterdam, The Netherlands.
Jazyk: angličtina
Zdroj: Psychiatry research [Psychiatry Res] 2023 Feb; Vol. 320, pp. 114997. Date of Electronic Publication: 2022 Dec 24.
DOI: 10.1016/j.psychres.2022.114997
Abstrakt: Objective: To determine whether gender and menopausal status moderate the response to antipsychotic medication in patients with schizophrenia.
Methods: We analyzed data of 22 short-term placebo-controlled registration trials of antipsychotic medications, which included 5,231 patients with schizophrenia. We applied two-step individual patient data meta-regression analyses to establish the influence of gender and menopausal status on treatment response in mean difference in symptom severity and difference in response (>30% symptom reduction). Analyses were performed both with and without correction for baseline (negative) symptom severity.
Results: Antipsychotic treatment is associated with larger mean symptom reduction in women than in men with schizophrenia. The number needed to treat (NNT) for a response in women was 6.9, in men 9.4. Although, we found an age by gender effect, the gender by treatment effect was independent of premenopausal status and baseline (negative) symptom severity.
Conclusion: In the treatment of schizophrenia we found evidence of a higher response to antipsychotic medication in women relative to men. We found no evidence that this effect was driven by menopausal status, or baseline (negative) symptom severity. Despite the impact of gender and age on effect size in acute antipsychotic treatment, efficacy was clinically relevant in all subgroups.
Competing Interests: Declaration of competing interest The authors have declared that there is no conflicts of interest in relation to the subject of this study.
(Copyright © 2022. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: